Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lung Cavity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Lung Cavity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-004189-37 Sponsor Protocol Number: HCQHNLcancer Start Date*: 2022-03-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer
    Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078181 Laryngeal squamous cell carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030964 Oral carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037352 Pulmonary carcinoma stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025123 Lung squamous cell carcinoma stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025122 Lung squamous cell carcinoma stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001256-22 Sponsor Protocol Number: GL0817-01 Start Date*: 2017-01-31
    Sponsor Name:Gliknik Inc
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients wi...
    Medical condition: Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004856 10026660 Malignant oral cavity neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) HU (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001994-25 Sponsor Protocol Number: TACTI-002(IMP321P015);KeynotePN798 Start Date*: 2019-02-12
    Sponsor Name:Immutep S.A.S.
    Full Title: TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurren...
    Medical condition: Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or recurrent or metastatic squamous head and neck cancer (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001743-12 Sponsor Protocol Number: INCB24360-208 Start Date*: 2018-07-04
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Maligna...
    Medical condition: Phase 1 (Dose Escalation): Advanced or metastatic solid tumors. Phase 2 (Dose Expansion): Advanced or metastatic non–small cell lung cancer (NSCLC), unresectable or metastatic melanoma (MEL) and r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-024496-37 Sponsor Protocol Number: 1716-12 Start Date*: 2012-05-04
    Sponsor Name:Virttu Biologics Limited
    Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002484-60 Sponsor Protocol Number: 2020-002484-6060 Start Date*: 2021-07-12
    Sponsor Name:Odense Universityhospital
    Full Title: Intrapleural Fibrinolysis and DNase versus VATS for the treatment of pleural empyema: a randomized, controlled trial.
    Medical condition: Pleural Empyema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.0 10021881 - Infections and infestations 10037381 Pulmonary empyema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004289-25 Sponsor Protocol Number: INCB24360-206 Start Date*: 2017-07-14
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced S...
    Medical condition: Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite Stable Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001122-22 Sponsor Protocol Number: BLUEPAT_FNUSA_2021 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice u sv. Anny v Brně
    Full Title: Subpleural lung nodules marking with blue dye substance and contrast agent under CT-guided control with subsequent videothoracoscopic wedge resection: prospective randomized study.
    Medical condition: Focal pulmonary lesions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10077488 Pulmonary resection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005219-16 Sponsor Protocol Number: GE-135-003 Start Date*: 2010-12-06
    Sponsor Name:GE Healthcare Ltd
    Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging
    Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004989-25 Sponsor Protocol Number: INCAGN1876-201 Start Date*: 2017-09-28
    Sponsor Name:Incyte Biosciences International Sàrl
    Full Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies.
    Medical condition: Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    20.0 100000017553 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 100000018529 10027150 Melanoma malignant LLT
    20.0 100000018548 10064025 Merkel cell carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 100000020977 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    11.0 100000005104 10038408 Renal cell carcinomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000599-40 Sponsor Protocol Number: Start Date*: 2012-06-13
    Sponsor Name:North Bristol NHS Trust
    Full Title: The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients
    Medical condition: Malignant pleural effusions
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035605 Pleural mesothelioma malignant advanced PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10066721 Pleural effusion recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035606 Pleural mesothelioma malignant localised LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035607 Pleural mesothelioma malignant recurrent PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10035598 Pleural effusion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035608 Pleural metastases LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061352 Pleural neoplasm PT
    14.1 10042613 - Surgical and medical procedures 10035612 Pleural therapeutic procedures HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10046099 Unspecified pleural effusion LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026673 Malignant pleural effusion PT
    14.1 10042613 - Surgical and medical procedures 10062754 Pleural cavity drainage LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10014313 Effusion pleural LLT
    14.1 10042613 - Surgical and medical procedures 10068942 Implantable pleural catheter insertion PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003921-40 Sponsor Protocol Number: 2016IF002 Start Date*: 2017-07-21
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust
    Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis
    Medical condition: Chronic Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154164 10003488 Aspergillosis LLT
    20.0 100000015649 10003493 Aspergillus fumigatus bronchopulmonary infection LLT
    20.0 100000154164 10003494 Aspergillus fumigatus infection LLT
    20.0 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 100000015649 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000421-76 Sponsor Protocol Number: AirGOs-biologics Start Date*: 2020-04-15
    Sponsor Name:Helsinki University Hospital
    Full Title: Aggravated airway inflammation: research on biological treatment (Mepolizumab) AirGOs-biologics
    Medical condition: A triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and NSAID exacerbated respiratory disease (NERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004374-25 Sponsor Protocol Number: 61528 Start Date*: 2020-03-25
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE
    Full Title: Thoracic duct identification with Indocyanine green fluorescence during minimally invasive esophagectomy with patient in prone position
    Medical condition: Chylothorax is a serioso post-operative complication, which occurs in 2-12% of patients undergoing esophagectomy. Thoracic duct lesion leads to a reduction of body fluids and albumin resulting in h...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10051228 Chylothorax PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003974-33 Sponsor Protocol Number: CE150171 Start Date*: 2021-05-25
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE
    Full Title: Thoracic duct identification with indocyanine green fluorescence during esophagectomy
    Medical condition: Chylothorax is a serious post-operative complication, with occurs in 2-12% of patients undergoing esophagectomy. Thoracic duct lesion leads to a reduction of body fluids and albumin resulting in hy...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10051228 Chylothorax PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004678-16 Sponsor Protocol Number: INCB24360-207 Start Date*: 2018-05-31
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
    Medical condition: Subjects with solid tumors of the type of colorectal cancer, pancreatic ductal adenocarcinoma, Squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, any solid tumor that pro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001359-36 Sponsor Protocol Number: CA223-001 Start Date*: 2016-07-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refracto...
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000443-27 Sponsor Protocol Number: KP-ELF01 Start Date*: 2012-06-12
    Sponsor Name:Dept. of Anesthesiology and Intensive Care, Charité - Campus Benjamin Franklin
    Full Title: Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem
    Medical condition: pneumonia complicated urinary infection complicated abdominal infection complicated skin and soft tissue infection acute bacterial meningitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10049582 Soft tissue infection NOS LLT
    20.0 100000004862 10040874 Skin infection NOS LLT
    20.0 100000004862 10046576 Urinary tract infection, site not specified LLT
    22.1 100000004862 10035725 Pneumonia NOS LLT
    20.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000653-23 Sponsor Protocol Number: TMC207-TiDP13-C210 Start Date*: 2012-06-13
    Sponsor Name:Janssen Infectious Diseases BVBA
    Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc...
    Medical condition: Multi-drug resistant tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2020-000627-40 Sponsor Protocol Number: IA-DUET Start Date*: 2020-12-28
    Sponsor Name:Erasmus MC
    Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA